A review on intrathecal administration of medications for leptomeningeal metastases in solid tumors
Leptomeningeal disease (LMD) is a particular mode of central metastasis in malignant tumors. It occurs when tumor cells infiltrate the subarachnoid space and cerebrospinal fluid (CSF), spreading throughout the central nervous system (CNS). LMD is a rare but devastating complication of malignant tumo...
Saved in:
Main Authors: | Xuemei Wang, Chi Yao, Li Quan, Junxiang Zhou |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2025-02-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1472945/full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Case report: A case report and literature review on the efficacy of high-dose aumolertinib combined intrathecal pemetrexed by Ommaya reservoir for EGFR-mutated NSCLC with leptomeningeal metastasis as the initial symptoms
by: Maoxi Zhong, et al.
Published: (2025-01-01) -
Clinical utility and predictive value of cerebrospinal fluid cell-free DNA profiling in non-small cell lung cancer patients with leptomeningeal metastasis
by: Sheng-Kai Liang, et al.
Published: (2025-02-01) -
Multiplex immunohistochemistry to explore the tumor immune microenvironment in HCC patients with different GPC3 expression
by: Mingzhen Zhou, et al.
Published: (2025-01-01) -
First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP:TGF-ß1 complex, as monotherapy and in combination with the anti–PD-1 antibody budigalimab in patients with advanced solid tumors
by: Toshio Shimizu, et al.
Published: (2024-10-01) -
Corrigendum: First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP: TGF-ß1 complex, as monotherapy and in combination with the anti–PD-1 antibody budigalimab in patients with advanced solid tumors
by: Toshio Shimizu, et al.
Published: (2025-01-01)